on the evening of January 12, Junshi Biology (688180.SH, stock price 37.95 yuan, market value 37.407 billion yuan) announced that the company held the 26th meeting of the third board of directors on the same day, deliberated and passed the proposal on the election of vice chairman and the proposal on the new appointment of general manager and chief executive officer.

Junshi Biology said that in order to improve and optimize the corporate governance structure, according to relevant regulations, after the qualification review of the nomination committee of the company's third board of directors, the company's board of directors elected NING LI (Li Ning) as the vice chairman of the third board of directors. From the date of deliberation and approval of the board of directors to the date of expiration of the term of the third board of directors.

In addition, due to post adjustment, NING LI (Li Ning) was elected as vice chairman and no longer served as general manager and chief executive officer of the company. The company will appoint NING LI (Li Ning) as the chairman of the company's wholly-owned subsidiary Toppley Biotechnology Co., Ltd. (TopAlliance Biosciences Inc.), responsible for the company's overseas business.

At the same time, the announcement also disclosed that after the nomination of the company's chairman Xiong Jun and the qualification review of the company's third board of directors nomination committee, the company's board of directors agreed to appoint Zou Jianjun as the company's general manager and chief executive officer to preside over the company's overall work. From the date of review and approval by the board of directors to the date of expiration of the third board of directors.

the resume information attached to the announcement shows that NING LI (Li ning), male, was born in October 1961. From January 2018 to January 2024, he served as the company's general manager and chief executive officer; since June 2018, he has served as the company's executive director. NING LI (Li Ning) received a bachelor's degree in medicine from Shanghai First Medical College in July 1984; graduated from Shanghai Medical University in October 1987 with a master's degree in medicine; graduated from the University of Iowa in August 1994 with a doctor's degree in preventive medicine/biostatistics. NING LI (Li Ning) served as a senior researcher at WESTAT of the National Institutes of Health (NIH)AIDS Research Cooperation Center from May 1994 to January 1997. From February 1997 to December 2009, he served as reviewer, senior reviewer, review team leader, branch director and other positions of the US Food and Drug Administration. From September 2009 to January 2018, he served as Sanofi Global R & D,Bridgewater, senior Director, Assistant Vice President and Vice President of Registration and Medical Policy of New Jersey Group; from January 2007 to December 2010, he served as an adjunct professor at Johns Hopkins (Johns Hopkins) University; from November 2010 to November 2012, he served as a visiting professor at the Clinical Research Institute of Peking University; from January 2012 to December 2014, he served as an adjunct professor at the Medical Informatics Center of Peking University.

Zou Jianjun, female, born in July 1971. From April 2022 to January 2024, he served as the company's deputy general manager and president of global research and development; since June 2022, he has served as the company's executive director. Zou Jianjun entered the Department of Clinical Medicine of the Fourth Military Medical University in 1989. He graduated in 1995 and received a bachelor's degree in clinical medicine. From August 1995 to September 2005, he served as a resident in the Oncology Department of the Clinical Medicine Department of the 301 Hospital of the People's Liberation Army and the Oncology Department of Shanghai Changzheng Hospital. Doctor and attending doctor, obtained a doctor's degree in clinical oncology from the Second Military Medical University in August 2005. From October 2005 to October 2012, he served as the medical manager, head of the treatment field, and head of global medical affairs of the Chinese oncology research and development department in Bayer Pharmaceuticals, Germany (New Jersey, US headquarters); from October 2012 to September 2015, Served as the head of Chinese medical affairs in the United States Xinji Pharmaceutical; from September 2015 to April 2022, he served as the chief medical officer and deputy general manager of Jiangsu Hengrui Pharmaceutical Co., Ltd.

Source of cover picture: every reporter Xu Libo